Edwards Lifesciences Corporation $EW is 2Xideas AG’s 4th Largest Position

2Xideas AG raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 173.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 520,711 shares of the medical research company’s stock after acquiring an additional 330,127 shares during the period. Edwards Lifesciences makes up approximately 7.0% of 2Xideas AG’s holdings, making the stock its 4th biggest holding. 2Xideas AG’s holdings in Edwards Lifesciences were worth $40,725,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its position in Edwards Lifesciences by 1.2% in the second quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock worth $5,474,515,000 after purchasing an additional 798,801 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after buying an additional 45,555 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Edwards Lifesciences by 15.7% in the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after buying an additional 1,584,958 shares during the last quarter. Norges Bank bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $580,640,000. Finally, Marshall Wace LLP raised its position in shares of Edwards Lifesciences by 127.5% during the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after buying an additional 3,864,908 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,314,725.84. This trade represents a 24.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Barclays reiterated an “overweight” rating and issued a $103.00 price target (up previously from $99.00) on shares of Edwards Lifesciences in a research report on Monday. Oppenheimer cut Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. BTIG Research reissued a “buy” rating and set a $103.00 target price (up previously from $100.00) on shares of Edwards Lifesciences in a research report on Thursday. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a research report on Monday, November 3rd. Finally, Stifel Nicolaus set a $100.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Friday. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $93.09.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $84.18 on Tuesday. The stock has a 50 day moving average price of $81.09 and a 200 day moving average price of $78.83. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The firm has a market capitalization of $48.85 billion, a P/E ratio of 36.28, a P/E/G ratio of 3.82 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the company posted $0.67 EPS. Edwards Lifesciences’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.